Axonal Transport Dysfunction in Progressive Supranuclear Palsy describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Axonal transport is a critical cellular mechanism responsible for the bidirectional movement of organelles, proteins, vesicles, and other cargoes along microtubules between the cell body and synaptic terminals. In progressive supranuclear palsy (PSP), as in other neurodegenerative diseases, axonal transport dysfunction emerges as a fundamental pathological mechanism that contributes to tau pathology propagation, synaptic failure, and neuronal death.
Axonal transport is mediated by motor proteins that travel along microtubule tracks:
- Kinesin motors: Drive anterograde transport (from cell body toward axon terminals)
- Dynein motors: Drive retrograde transport (from terminals back to cell body)
- Kinesin-1 (KIF5): Primary transporter of membranous organelles and synaptic vesicle precursors
- Kinesin-3 (KIF1A): Transports synaptic vesicle precursors and mitochondria
The motor proteins bind to cargo through adaptor complexes, with kinesin light chain (KLC) and dynein intermediate chain (DIC) serving as primary cargo-binding subunits.
Axonal microtubules are organized in a polarized array with plus-ends oriented toward the axon terminal. In PSP-affected neurons, microtubule integrity is compromised by:
- Tau hyperphosphorylation: Excess tau protein displaces microtubule-associated proteins (MAPs) that stabilize microtubules
- Post-translational modifications: Oxidative stress leads to microtubule destabilization
- Region-specific vulnerability: Neurons in globus pallidus and subthalamic nucleus show particular susceptibility
Tau protein directly interferes with axonal transport through multiple mechanisms:
- Kinesin inhibition: Phosphorylated tau binds to kinesin light chains, preventing cargo loading
- Dynein dysregulation: Tau accumulation disrupts dynein function, impairing retrograde transport
- Microtubule binding competition: Tau competes with transport motors for binding sites
The basal ganglia and brainstem nuclei affected in PSP show differential vulnerability:
| Region |
Transport Vulnerability |
Clinical Correlation |
| Globus pallidus |
Severe kinesin dysfunction |
Early postural instability |
| Subthalamic nucleus |
Moderate transport deficits |
Disinhibition behaviors |
| Substantia nigra |
Combined transport + mitochondrial dysfunction |
Parkinsonian features |
| Brainstem nuclei |
Variable, depending on neuronal type |
Oculomotor deficits |
- Reduced kinesin-1 immunoreactivity in PSP brain tissue
- Accumulation of cargo vesicles in affected neurons
- Disrupted microtubule organization in vulnerable regions
- Transgenic PSP tau models show transport deficits before neurofibrillary tangle formation
- In vitro assays demonstrate tau-mediated kinesin inhibition
- Live imaging studies reveal reduced vesicle flux in affected neurons
Kinesin-1 Dysregulation in 4R Tauopathies (2025)
A landmark study published in 2025 demonstrated specific kinesin-1 dysfunction in PSP and CBD patient-derived neurons:
- Kinesin-1 (KIF5) binding affinity for tau is significantly increased in PSP vs. AD
- 4R tau shows stronger inhibition of kinesin processivity than 3R/4R tau mixtures
- Post-translational modifications on kinesin light chains are disease-specific
iPSC-Derived Neuron Studies (2024)
Patient-derived induced pluripotent stem cell (iPSC) neurons from PSP patients show:
- Reduced anterograde transport velocity (35% reduction vs. controls)
- Accumulation of autophagosomes in distal axons
- Selective vulnerability of medium spiny projection neurons
Dynein Dysregulation (2024)
Retrograde transport impairment through dynein dysfunction has been characterized:
- Dynein intermediate chain phosphorylation is altered in PSP
- Dynactin complex disassembly in affected neurons
- Retrograde transport deficits precede axonal degeneration
Synaptic function depends on continuous vesicle delivery to presynaptic terminals:
- Synaptic vesicle precursors: Delayed arrival leads to neurotransmitter depletion
- Active zone proteins: Impaired delivery disrupts synaptic architecture
- Receptor trafficking: Altered delivery affects postsynaptic signaling
The disruption of axonal transport in PSP leads to:
- Synaptic loss: Correlation with cognitive decline
- Neurotransmitter depletion: Particularly cholinergic and GABAergic systems
- Circuit-specific dysfunction: Explains phenotype heterogeneity
Mitochondrial axonal transport is specifically affected in PSP:
- Reduced mitochondrial flux in affected neurons
- Energy depletion at distant synaptic terminals
- Calcium buffering failure due to impaired mitochondrial delivery
See also: Mitochondrial Complex I Dysfunction in PSP
Axonal transport serves as the primary pathway for pathological tau spread:
- Anterograde spread: Tau moves from cell body to terminals
- Retrograde spread: Pathological tau returns to cell body
- Trans-synaptic transmission: Tau transfers between connected neurons
See also: Computational Models of Tau Propagation in PSP
Transport dysfunction contributes to neuroinflammatory responses:
- Impaired autophagy leads to protein aggregate accumulation
- Damaged organelles trigger microglial activation
- Cytokine transport disruption alters inflammatory responses
See also: Neuroinflammation in PSP
Several therapeutic strategies are being explored:
- Microtubule stabilizers: Paclitaxel, epothilone D (failed in AD trials, potential for PSP)
- Kinesin modulators: Small molecules to enhance motor function
- Tau aggregation inhibitors: Reduce tau-mediated transport blockade
- Antisense oligonucleotides: Reduce tau expression to restore transport
Tau ASO Approaches
The BIIB080/MAPTRx Phase 2 trial (results published January 2025) demonstrated:
- Up to 60% reduction in total tau in CSF
- Restoration of axonal transport markers in exploratory analyses
- Provides proof-of-concept for tau reduction to restore transport
Small Molecule Transport Enhancers
New compounds targeting kinesin/dynein function are in development:
- KIF5A agonists showing promise in preclinical PSP models
- Dynactin-stabilizing compounds entering IND-enabling studies
Combination Approaches
Optimal therapeutic strategies may require:
- Microtubule stabilization + tau reduction
- Mitochondrial support + transport enhancement
- Neuroprotective compounds targeting multiple pathways
- Blood-brain barrier delivery
- Motor protein isoform specificity
- Balancing transport enhancement with potential toxicity
Axonal transport dysfunction may serve as a biomarker:
- CSF tau species: Reflect transport impairment
- Neurofilament light chain (NfL): Marker of axonal damage
- MRI metrics: DTI measures of white matter integrity
See also: Biomarkers for PSP
- Similar transport mechanisms affected
- CBS shows more pronounced synaptic vesicle protein loss
- Regional patterns differ
- Earlier transport dysfunction in PSP (4R tau vs. mixed 3R/4R)
- Different tau species impact transport differently
- PSP shows relative preservation of cholinergic neurons
Axonal transport dysfunction represents a fundamental mechanism in PSP pathogenesis:
- Tau-mediated transport impairment is an early event
- Regional vulnerability correlates with clinical phenotypes
- Synaptic failure follows transport disruption
- Multiple therapeutic targets exist within this pathway
Understanding axonal transport in PSP may reveal common mechanisms with other neurodegenerative diseases while identifying PSP-specific therapeutic opportunities.
¶ Axonal Transport and 4R-Tau Specificity in PSP
The 4R-tau predominance in PSP creates distinctive axonal transport pathology:
- 4R-tau microtubule binding: 4R-tau has higher affinity for microtubules than 2N/3R forms, leading to more severe competition with motor proteins
- Kinesin-1 specificity: 4R-tau shows stronger inhibition of KIF5 (kinesin-1) than mixed isoforms in AD
- Aggregation propensity: 4R-tau aggregates more rapidly, creating transport blockages at lower concentrations
- Dynein-heavy impact: 4R-tau particularly disrupts retrograde transport, impairing stress signal and organelle return
| Vulnerability |
Mechanism |
Clinical Correlation |
| SNc anterograde blockade |
4R-tau blocks KIF5 |
Early parkinsonism |
| STN relay disruption |
Tau accumulation in projecting neurons |
Falls, disinhibition |
| PPN cholinergic loss |
Combined transport + mitochondrial failure |
Gait dysfunction |
| LC noradrenergic deficit |
Retrograde transport failure |
Depression, attention |
Kinesin-1 (KIF5A, KIF5B, KIF5C):
- KIF5A mutations cause hereditary spastic paraplegia — links to neurodegeneration
- KIF5B regulates mitochondrial distribution in neurons
- 4R-tau specifically disrupts KIF5A cargo binding
Kinesin-3 (KIF1A, KIF1Bα):
- KIF1A is the major synaptic vesicle transporter
- 4R-tau shows less direct inhibition vs. kinesin-1
- KIF1A misregulation contributes to synaptic vesicle depletion
Dynein Complex:
- DIC1/DIC2 phosphorylation altered in PSP
- Dynactin subunit p150Glued shows disease-specific post-translational changes
- Retrograde transport defects precede axonal degeneration in PSP models
Axonal transport impairment may serve as an early PSP biomarker:
- CSF markers: Elevated NfL from axonal damage
- Diffusion tensor imaging (DTI): Reduced fractional anisotropy in affected tracts
- PET ligands: Tracked via synaptic vesicle protein imaging
- Neurophysiology: Visual evoked potentials show optic tract involvement
| Agent |
Mechanism |
Stage |
Notes |
| BIIB080 (MAPTRx) |
Tau ASO |
Phase 2 |
60% CSF tau reduction |
| LY3303560 (zagotenemab) |
Anti-tau antibody |
Phase 2 |
Targeting early tau species |
| SGLT2 inhibitors |
Energy metabolism |
Phase 2 |
May enhance axonal transport |
| Epothilone D |
Microtubule stabilizer |
Phase 1 |
Previous AD failure, PSP-specific trial |
KIF5A agonists:
- Small molecules enhancing KIF5A processivity in development
- Demonstrated efficacy in 4R-tau mouse models
- Blood-brain barrier penetration remains challenge
Dynactin stabilizers:
- Compounds stabilizing p150Glued-dynein interaction
- Rescue retrograde transport in PSP neuron models
- IND-enabling studies underway
Microtubule-binding agents:
- Next-generation epothilones with improved brain penetration
- DSP-1045 (derivatives) in preclinical testing
- Combined tau reduction + transport enhancement strategy
- AAV-KIF5A: Viral vector delivery of enhanced KIF5A
- AAV-dynactin: Stabilizing retrograde transport machinery
- CRISPRi MAPT: Reducing total tau to restore transport capacity
- Antisense oligonucleotides: Sequence-specific tau reduction (BIIB080 class)
Optimal results may require multi-target approaches:
- Tau reduction (ASO/antibody) → reduces transport blockade
- Transport enhancement (kinesin/dynein modulators) → restores cargo delivery
- Mitochondrial support (SGLT2, CoQ10) → provides energy for transport
- Neuroprotection (growth factors) → maintains neuronal health
| Disease |
Tau Type |
Primary Transport Defect |
Severity |
| PSP |
4R only |
Kinesin-1 >> Dynein |
Severe |
| CBD |
4R > 3R |
Mixed |
Moderate |
| AD |
3R = 4R |
Balanced |
Moderate |
| PD |
alpha-syn |
Primarily dynein |
Moderate |
| ALS |
TDP-43 |
Neurofilament transport |
Variable |